Hyperfine Overview - Hyperfine's Swoop system is the first FDA-cleared, AI-powered portable MR brain imaging system, targeting a market opportunity exceeding $6 billion[4, 74] - The company's growth strategy is supported by the launch of the next-generation Swoop system and Optive AI software, which enhances image quality for ultra-low field MRI[4] - Hyperfine has secured approximately 200 patents related to its proprietary technology[9] Market and Expansion - The company is targeting expansion across multiple sites of care, including inpatient, outpatient, and community settings, with a total addressable market (TAM) potentially exceeding $16 billion[8] - Hyperfine has an installed base of over 190 Swoop systems globally[52] - The company estimates a potential US Swoop system revenue of $100 million for every 1.5% market penetration[54] Financial Performance - Q3 2025 revenue reached $3.4 million, representing a 27% sequential increase[58] - The effective average selling price (ASP) for the Swoop system in Q3 2025 was approximately $360,000[58] - Cash burn decreased to $5.9 million in Q3 2025, a 27% reduction compared to the previous quarter[59]

Financial Highlights - TMC has $165 million in liquidity as of November 13, 2025, excluding in-the-money warrants [8] - Potential proceeds from Class A and Class C warrants that are in-the-money today is approximately $54 million [14] - Q3 2025 operating loss was $55.3 million, compared to $19.9 million in Q3 2024 [84] - The company's cash balance increased mainly due to proceeds from warrants and stock options, with $7.1 million in proceeds in Q3 2025 and $12.8 million in October 2025 [11, 12] Resource and Production - A billion-tonne resource could supply the US with manganese for 330 years, cobalt for 95 years, nickel for 210 years, and copper for 5 years [18, 20] - The company estimates first production in Q4 2027 [65] - The PFS NPV is $5.5 billion, and the IA NPV is $18.1 billion, resulting in a combined NPV of $23.6 billion [62, 67] - The Pre-Feasibility Study (PFS) projects revenue of $595 per dry tonne of nodules, with an EBITDA of $254 per dry tonne (43% margin) [72, 73] Regulatory and Strategic - The US depends entirely on imports for primary nickel, manganese, and cobalt, and 45% for copper [15, 16] - NOAA is streamlining the review of applications for Exploration Licenses (ELs) and Commercial Recovery Permits (CRPs) [32] - The United States and Japan will collaborate on developing rare earth minerals from Japan's seafloor [25]

Company Overview & Strategy - HeartBeam aims to shift cardiac care from hospitals to home, similar to trends seen with glucose, blood pressure, and oxygen monitors[15, 16] - The company's synthesized 12-Lead ECG system, combined with on-demand cardiologist interpretation, is the foundation for a new cardiac care model[21] - HeartBeam is building an ecosystem around its core technology to deepen patient engagement and provide actionable insights for physicians[21, 23] - The company's near-term commercial strategy focuses on creating a new category, market entry through pilot programs, a focused commercial model, and patient retention[30] Regulatory & Clinical Milestones - HeartBeam received foundational FDA clearance for its system for arrhythmia assessment in December 2024[9, 13, 25] - FDA 510(k) clearance for the 12-Lead ECG Synthesis Software for arrhythmia assessment is anticipated in Q4 2025[13, 25, 34] - A pivotal clinical study (VALID-ECG) showed 93.4% overall diagnostic agreement for arrhythmia assessment[25] - New data presented at AHA Scientific Sessions in November 2025 supports HeartBeam's potential for early heart attack detection[27] Financial Performance (Q3 2025) - Total operating expenses were $5290 thousand[31] - Net loss was $5255 thousand, with an Earnings per Share (EPS) of $(0.15)[31] - Net cash used in operating activities was $3160 thousand, an 8% decrease quarter-over-quarter[31, 33] - Cash and cash equivalents and short-term investments totaled $1856 thousand as of September 30, 2025[31]

Market Opportunity and Growth - The total market for generative AI is projected to reach a five-year CAGR of 73.5% by 2028[5] - Worldwide IT services spending is expected to reach $2.1 trillion by 2027[6] - The digital business services market is estimated to reach $702 billion by 2027[6] - 90% of service providers will use generative AI for software development services by 2027[7] - Global spending on product engineering and operational technology services is forecasted to reach $334 billion by 2027[7] - Generative AI's annual spending worldwide is projected to reach $151 billion by 2027[7] Financial Performance - The company's Last Twelve Months (LTM) Q3'25 total revenue is $2.5 billion[34] - The company's revenue Compound Annual Growth Rate (CAGR) from 2014 to 2024 was 28.3%[34, 40] - The company's LTM Q3'25 revenue per IT professional is $90.3K[34] - The company's Q3'25 adjusted gross profit margin is 38.1%[34] - The company's Q3'25 adjusted profit from operations margin is 15.5%[34]

Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation November 2025 Important Notices & Disclaimers This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements we make regarding BioAtla's business plans and prospects; whet ...

Financial Performance - Revenue reached $7.4 million, a 21% increase compared to Q3 2024[13] - Core revenue increased by 12% compared to Q3 2024[13] - Non-GAAP gross margin improved to 46%, significantly higher than the 26% in Q3 2024[13] - Non-GAAP operating expenses decreased by 40% compared to Q3 2024, totaling $9.7 million[13] Operational Highlights - Flowcells sold increased by 7% to 8,390 compared to Q3 2024[13] - The OGM installed base grew by 4% compared to Q3 2024, reaching 384 systems[13] - Seven new OGM installations were completed in Q3 2025, bringing the year-to-date total to 23[13] Strategic Focus and Outlook - The company completed a $10 million public offering of common stock in September 2025[13] - Cash, cash equivalents, and available-for-sale securities totaled $31.8 million as of September 30, 2025[13] - The company is reiterating its full-year 2025 revenue guidance of $26 - $30 million[30] - The company expects new OGM installations to surpass 25 systems for FY 2025, exceeding prior expectations of 20-25 systems[30]

Owlet, Inc. (NYSE: OWLT) Q3 2025 Financial Results November 13, 2025 1 March 4, 2025 Owlet, Inc. (NYSE: OWLT) | Q3 2025 Financial Results Conference Call Speakers Webcast Contacts Confidential | 2 ● Jonathan Harris, CEO & President ● Amanda Twede Crawford, CFO ● Jay Gentzkow, VP Investor Relations and Corporate Development ● Domestic Callers: (833) 470-1428 ● International Callers: (646) 844-6383 ○ Access Code: 428622 ● Webcast Archive Available: investors.owletcare.com ● Website: investors.owletcare.com ● ...

Q3 2025 Performance Highlights - Shimmick Projects revenue increased by 6% year-over-year[8] - Gross margin on Shimmick Projects increased by 67% year-over-year[8] - Backlog increased by 15% quarter-over-quarter, with a book-to-burn ratio of 1.7x, exceeding 1.0 for the first time since 2023[8] - The company achieved its first positive Adjusted EBITDA in four quarters, reporting $4 million[8] - New awards of $60 million were added to the backlog in October 2025, and $169 million in projects were selected as preferred bidder with awards pending[8] Revenue and Gross Margin Details - Reported revenue was $142 million, with $107 million from Shimmick Projects[8] - Excluding a one-time favorable GGB Project claim settlement revenue of $31 million in Q3 2024, revenue increased by $7 million, or 5% year-over-year[8] - Reported gross margin was $11 million, compared to $12 million in Q3 2024[8] - Excluding a one-time favorable GGB Project claim settlement gross margin of $11 million in Q3 2024, gross margin increased by $10 million year-over-year[8] - Shimmick Projects contributed a gross margin of $10 million, up 67% year-over-year, while Non-Core Projects contributed $1 million[8] Backlog and Future Outlook - Backlog is approximately $754 million as of October 3, 2025, with $191 million in new work added in Q3 2025, and Shimmick Projects accounting for over 86% of the total backlog[8] - The company's pipeline supports monthly bidding activity of $600 million to $1 billion[10] - For the fiscal year ending January 2, 2026, the company reaffirms its guidance, expecting Shimmick Projects revenue in the range of $405 million to $415 million, with gross margin between 9% and 12%[24] - Non-Core Projects revenue is expected to be in the range of $80 million to $90 million, with gross margin between -15% and -5%[24] - Consolidated Adjusted EBITDA is expected to be between $5 million and $15 million[24]

Opening video 2025 Investor Day 2 Built for growth November 13, 2025 2025 Investor Day 1 2025 Investor Day Jason Beach Vice President, Finance and Investor Relations 2025 Investor Day 3 Agenda | Built for growth | Kevin Lobo, Chair and Chief Executive Officer | | --- | --- | | Customer -focused innovation | Spencer Stiles, Group President, Orthopaedics | | Spotlight: Power brands | Dylan Crotty, President, Instruments | | Spotlight: Mako 4 and Triathlon Gold | Kathy Truppi, President, Joint Replacement | | ...

Wolfe Research Wealth Symposium November 13, 2025 Disclaimer Forward-Looking Statements This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks, assumptions, and uncertainties, including statements relating to the market opportunity and future business prospects of Stifel Financial Corp., as well as Stifel, Nicolaus & Company, Incorporated and its subsidiaries (collectively, "SF" or the "Company"). T ...